Dr Deanna J Willis, MD | |
7101 Jahnke Rd, Richmond, VA 23225-4017 | |
(804) 483-0000 | |
Not Available |
Full Name | Dr Deanna J Willis |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Experience | 10 Years |
Location | 7101 Jahnke Rd, Richmond, Virginia |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861812422 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | 0101261911 (Virginia) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Medical College Of Virginia Hospitals | Richmond, VA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mcv Associated Physicians | 4385542117 | 1312 |
News Archive
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Repros Therapeutics (Nasdaq:RPRX) today announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.
› Verified 7 days ago
Entity Name | Mcv Associated Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1710959457 PECOS PAC ID: 4385542117 Enrollment ID: O20031230000559 |
News Archive
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Repros Therapeutics (Nasdaq:RPRX) today announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.
› Verified 7 days ago
Entity Name | Cmh Physician Services Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1194760645 PECOS PAC ID: 3779551445 Enrollment ID: O20040921000171 |
News Archive
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Repros Therapeutics (Nasdaq:RPRX) today announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.
› Verified 7 days ago
Entity Name | Emergency Coverage Corp |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20050418000414 |
News Archive
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Repros Therapeutics (Nasdaq:RPRX) today announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.
› Verified 7 days ago
Entity Name | Richmond Emergency Physicians, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1134374978 PECOS PAC ID: 7517021652 Enrollment ID: O20090204000205 |
News Archive
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Repros Therapeutics (Nasdaq:RPRX) today announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Deanna J Willis, MD 103 Woodhall Dr, Richmond, VA 23229-7326 Ph: (540) 270-6236 | Dr Deanna J Willis, MD 7101 Jahnke Rd, Richmond, VA 23225-4017 Ph: (804) 483-0000 |
News Archive
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.
Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors.
CellAura, the leading producer of fluorescence reagents for drug discovery and life sciences research, today announced a development partnership with Cisbio Bioassays. Under the terms of the agreement, CellAura will provide pharmacologically validated reagents to Cisbio Bioassays that will be applied to Cisbio Bioassays' Tag-lite™ range of non-radioactive assays for cellular studies.
Repros Therapeutics (Nasdaq:RPRX) today announced that Repros has entered into a definitive agreement with a single institutional investor to sell 1.5 million shares of its common stock at $0.65 per share for gross proceeds of approximately $1.0 million.
› Verified 7 days ago
Robert Weisberger, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Dr. Michael Ferebee, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1602 Skipwith Rd, Richmond, VA 23229 Phone: 757-329-3754 | |
James R Shefferly, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Virginia Emergency Associates Inc, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Jeffry A Zimmerman, P.A. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5801 Bremo Rd, St Francis Emergency Department, Richmond, VA 23226 Phone: 804-287-7066 Fax: 804-673-9531 | |
Shawn M Borich, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Rockbridge St Ste 103, Richmond, VA 23230 Phone: 804-386-0200 | |
Tamera Barnes, MD, FACEP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7101 Jahnke Rd, Richmond, VA 23225 Phone: 804-330-2000 | |
Dr. Kevin James Noreika, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1401 Johnston Willis Dr, Richmond, VA 23235 Phone: 804-330-2277 |